ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Mar 09, 2022 16:06 JST
Source: Eisai
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500)
TOKYO, Mar 09, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi.
Under the Certified Health and Productivity Management Outstanding Organization Recognition Program, the Nippon Kenko Kaigi examines large enterprises, small and medium enterprises and other organizations engaging in initiatives for overcoming health-related challenges in regional communities or for promoting health-conscious activities led by the Nippon Kenko Kaigi. It recognizes outstanding enterprises engaging in efforts for health and productivity management by evaluating from a business-management perspective based on following criteria: "management philosophy and policies", "organized frameworks", "systems and implementation of measures", and "evaluation and improvement". Eisai exceeded the average of its industry peers in all criteria, receiving particularly high scores for such as the "information disclosure and dissemination to other companies" (in the criteria of management philosophy and policies), "well adopted by employees" (in the criteria of organized frameworks), "lifestyle improvement" and "other measures*" (in the criteria of systems and implementation of measures). The program was launched in 2017, and this is the fourth time that Eisai was certified as a "White 500" company.
Eisai issued the "Eisai Health Declaration" in 2019, and has strategically implemented health management for employees from a management perspective.
Eisai will continue to promote its efforts toward practicing the health and productivity management and to further contribute to increasing the benefits of patients and their families.
Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides. Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word.
Eisai regards its employees as an important stakeholder and asset for the realization of its hhc philosophy.
Eisai believes that its commitment to maintaining and improving the health of human resources is fundamental to develop highly engaged employees who are motivated to contribute voluntarily toward the realization of the hhc philosophy.
*Measures to address health issues specific to women and the elderly, long working hours, mental health, dependents of the company's employees, and prevention of infectious disease during COVID-19 pandemic.
Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Sectors: Healthcare & Pharm
Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Corporation: Seven-Member Partnership Commits to Warehouse DX Initiative
Jul 01, 2022 16:10 JST
NEC Expands Global Solutions Delivery Capacity with Acquisition of Aspire Technology, a Network Solutions and System Integration Company
Jul 01, 2022 12:47 JST
MC and Maruha Nichiro Agree to Establish New Joint Venture in Salmon (land-based)
Jun 30, 2022 18:23 JST
DOCOMO and CyberAgent to Establish New Advertising Company: Prism Partner Inc.
Jun 30, 2022 18:04 JST
MHIENG's First Compact CO2 Capture System Goes into Commercial Operation at Biomass Power Plant in Hiroshima
Jun 30, 2022 14:44 JST
Mazda Production and Sales Results for May 2022
Jun 30, 2022 13:33 JST
Milestone of THz Communication
Jun 29, 2022 16:48 JST
Infinera and NEC to Modernize Neutral Networks' Mexico to United States Fiber Optic Network with Industry-leading ICE6 800G Solution
Jun 29, 2022 15:35 JST
Fujitsu Recognized as Winner of 2022 Microsoft Education Partner of the Year Award
Jun 29, 2022 11:18 JST
Hitachi High-Tech Launches the AFM100 Pro High-Sensitivity Scanning Probe Microscope System with Improved Detection Sensitivity
Jun 28, 2022 16:51 JST
Hokkaido University and NEC conclude an agreement for developing spatial sensing to combat the spread of illness
Jun 28, 2022 15:53 JST
Fujitsu global survey demonstrates how 'digital first' approach helps to accelerate sustainability transformation
Jun 28, 2022 12:26 JST
E.Design Insurance and Eisai Enter Into Business Alliance
Jun 28, 2022 10:20 JST
GR YARIS Rally1 wins African epic with incredible 1-2-3-4 finish
Jun 27, 2022 10:50 JST
Toyota and Suzuki to Deepen Collaboration in the Fields of Development and Production in India
Jun 24, 2022 19:16 JST
Murata and Mitsubishi Agree on a Cooperative Framework for Working Toward a Carbon-Neutral Society
Jun 24, 2022 18:22 JST
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
Jun 24, 2022 11:55 JST
Honda Joins Sustainable Aviation Fuel Review Panel
Jun 24, 2022 10:42 JST
TOYOTA GAZOO Racing announces team setup for Nurburgring Endurance Series
Jun 23, 2022 17:54 JST
MHI Invests in Electric Hydrogen, a U.S. Startup, to Accelerate Efforts to Produce Clean Hydrogen at Scale
Jun 23, 2022 14:31 JST
More Latest Release >>
Related Release
E.Design Insurance and Eisai Enter Into Business Alliance
6/28/2022 10:20:00 AM JST
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
6/24/2022 11:55:00 AM JST
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
6/22/2022 2:05:00 PM JST
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
6/6/2022 3:05:00 PM JST
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
6/3/2022 4:37:00 PM JST
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
5/27/2022 12:49:00 PM JST
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
5/27/2022 12:24:00 PM JST
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
5/10/2022 11:23:00 AM JST
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
5/10/2022 11:00:00 AM JST
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
4/1/2022 2:05:00 PM JST
More Press release >>